NL
NTLA icon

NWAM LLC’s Intellia Therapeutics NTLA Stock Holding History

NWAM LLC’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Hold
19,540
– – 0.01% 545
2025
Q4 		$273K Buy
19,540
+9,040
+86% +$124K 0.02% 523
2025
Q3 		$294K Buy
+10,500
New +$129K 0.02% 524

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NWAM LLC's NTLA Position: Q1 2026 in Review

NWAM LLC held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 19,540 shares worth $251K. The position accounts for 0.01% of the portfolio, ranked #545.

NWAM LLC first reported a position in NTLA in Q3 2025 and has held it in 3 quarters since. The position peaked at $294K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • NWAM LLC held 19,540 shares of Intellia Therapeutics worth $251K as of Q1 2026.
  • NWAM LLC left its Intellia Therapeutics share count unchanged in Q1 2026.
  • Intellia Therapeutics made up 0.01% of NWAM LLC's portfolio in Q1 2026, its #545 holding.
  • NWAM LLC first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • NWAM LLC's Intellia Therapeutics position peaked at $294K in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on NWAM LLC's 13F filing for Q1 2026, filed 4 May 2026.